Usana Health Sciences

USNA

Market cap $370M

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and instituti.

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks is more attractive to value investors?

SALT LAKE CITY, April 1, 2026 /PRNewswire/ -- For World Health Day April 7, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE: USNA), is calling for a shift away from awareness only and toward execution to improve health. "Most people know how to improve their health; they just don't do it consistently," said Guest.

SALT LAKE CITY, March 24, 2026 /PRNewswire/ -- USANA (NYSE: USNA), a global leader in cellular nutrition, today announced that its flagship CellSentials supplement has earned the prestigious ConsumerLab.com Seal of Approval. This highly respected third-party certification is awarded only to products that meet rigorous standards for purity, potency, and label accuracy.

Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

USANA Health (USNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Ford, USANA, Strategic Education, Patria Investments and Concentrix are some low P/B picks, signaling potential undervaluation and growth prospects.

USANA Health (USNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Value plays STRA, USNA, ARW and USB screen cheap on price-to-cash-flow as Middle East tensions and tariff worries keep markets volatile.

USANA Health Sciences is executing a strategic pivot from its declining MLM core to high-growth brands Hiya and Rise Wellness. Hiya's Disney collaboration and subscription model drive projected 23% revenue growth, while Rise Wellness secures major retail distribution for Protein Pop. USNA trades at a significant valuation discount (EV/EBITDA 2.67), with a projected 2026 target price of $24.33—25% above current levels.